Vasoactivity of rucaparib, a PARP-1 inhibitor, is a complex process that involves myosin light chain kinase, P2 receptors, and PARP itself
McCrudden, Cian M, O'Rourke, Martin G, Cherry, Kim E, Yuen, Hiu-Fung, O'Rourke, Declan, Babur, Muhammad, Telfer, Brian A, Thomas, Huw D, Keane, Patrick, Nambirajan, Thiagarajan, Hagan, Chris, O'Sullivan, Joe M, Shaw, Chris, Williams, Kaye J, Curtin, Nicola J, Hirst, David G, Robson, Tracy
Published in PloS one (17.02.2015)
Published in PloS one (17.02.2015)
Get full text
Journal Article